Literature DB >> 9794509

Dodecylmaltoside-mediated nasal and ocular absorption of lyspro-insulin: independence of surfactant action from multimer dissociation.

D J Pillion1, S Hosmer, E Meezan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9794509     DOI： 10.1023/a:1011975721569

Source DB:  PubMed          Journal:  Pharm Res        ISSN： 0724-8741            Impact factor:   4.200


× No keyword cloud information.
  13 in total

1.  Intranasal administration of insulin with phospholipid as absorption enhancer: pharmacokinetics in normal subjects.

Authors:  K Drejer; A Vaag; K Bech; P Hansen; A R Sørensen; N Mygind
Journal:  Diabet Med       Date:  1992-05       Impact factor: 4.359

2.  Intranasal insulin therapy: the clinical realities.

Authors:  J Hilsted; S Madsbad; A Hvidberg; M H Rasmussen; T Krarup; H Ipsen; B Hansen; M Pedersen; R Djurup; B Oxenbøll
Journal:  Diabetologia       Date:  1995-06       Impact factor: 10.122

3.  Nasal absorption of insulin in dogs.

Authors:  S Harai; T Ikenaga; T Matsuzawa
Journal:  Diabetes       Date:  1978-03       Impact factor: 9.461

4.  Reduction of blood glucose concentration with insulin eye drops.

Authors:  G C Chiou; C Y Chuang; M S Chang
Journal:  Diabetes Care       Date:  1988-10       Impact factor: 19.112

5.  Efficacy of insulin eyedrops.

Authors:  D J Pillion; J A Atchison; J Stott; D McCracken; C Gargiulo; E Meezan
Journal:  J Ocul Pharmacol       Date:  1994

6.  Alkylglycosides enhance systemic absorption of insulin applied topically to the rat eye.

Authors:  D J Pillion; J A Atchison; R X Wang; E Meezan
Journal:  J Pharmacol Exp Ther       Date:  1994-12       Impact factor: 4.030

7.  [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin.

Authors:  D C Howey; R R Bowsher; R L Brunelle; J R Woodworth
Journal:  Diabetes       Date:  1994-03       Impact factor: 9.461

8.  Glucagon administration to the rat via eye drops.

Authors:  D J Pillion; D L McCracken; M Yang; J A Atchison
Journal:  J Ocul Pharmacol       Date:  1992

9.  Insulin delivery in nosedrops: new formulations containing alkylglycosides.

Authors:  D J Pillion; J A Atchison; C Gargiulo; R X Wang; P Wang; E Meezan
Journal:  Endocrinology       Date:  1994-12       Impact factor: 4.736

10.  Insulin administered intranasally as an insulin-bile salt aerosol. Effectiveness and reproducibility in normal and diabetic subjects.

Authors:  A C Moses; G S Gordon; M C Carey; J S Flier
Journal:  Diabetes       Date:  1983-11       Impact factor: 9.461
View more
  8 in total

Review 1.  Absorption enhancers for nasal drug delivery.

Authors:  Stanley S Davis; Lisbeth Illum
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

2.  Mutual inhibition of the insulin absorption-enhancing properties of dodecylmaltoside and dimethyl-beta-cyclodextrin following nasal administration.

Authors:  F Ahsan; J J Arnold; E Meezan; D J Pillion
Journal:  Pharm Res       Date:  2001-05       Impact factor: 4.200

3.  Enhanced bioavailability of calcitonin formulated with alkylglycosides following nasal and ocular administration in rats.

Authors:  F Ahsan; J Arnold; E Meezan; D J Pillion
Journal:  Pharm Res       Date:  2001-12       Impact factor: 4.200

4.  Intranasal administration of recombinant Neisseria gonorrhoeae transferrin binding proteins A and B conjugated to the cholera toxin B subunit induces systemic and vaginal antibodies in mice.

Authors:  Gregory A Price; Michael W Russell; Cynthia Nau Cornelissen
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

5.  Nasal absorption of mixtures of fast-acting and long-acting insulins.

Authors:  Dennis J Pillion; Michael D Fyrberg; Elias Meezan
Journal:  Int J Pharm       Date:  2010-01-18       Impact factor: 5.875

6.  In vitro assessment of alkylglycosides as permeability enhancers.

Authors:  J G Eley; P Triumalashetty
Journal:  AAPS PharmSciTech       Date:  2001-10-19       Impact factor: 3.246

7.  Basics and recent advances in peptide and protein drug delivery.

Authors:  Benjamin J Bruno; Geoffrey D Miller; Carol S Lim
Journal:  Ther Deliv       Date:  2013-11

8.  A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine.

Authors:  Sagar Munjal; Elimor Brand-Schieber; Kent Allenby; Egilius L H Spierings; Roger K Cady; Alan M Rapoport
Journal:  J Headache Pain       Date:  2017-03-01       Impact factor: 7.277
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.